Market Overview

Reata Pharmaceuticals: Q2 Earnings Insights


Shares of Reata Pharmaceuticals (NASDAQ:RETA) were unchanged after the company reported Q2 results.

Quarterly Results

Earnings per share decreased 7.89% year over year to ($1.23), which beat the estimate of ($2.84).

Revenue of $3,073,000 decreased by 60.77% from the same period last year, which beat the estimate of $1,040,000.


Earnings guidance hasn't been issued by the company for now.

Reata Pharmaceuticals hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: Aug 10, 2020

Time: 08:30 AM

ET Webcast URL:

Recent Stock Performance

Company's 52-week high was at $257.96

52-week low: $70.00

Price action over last quarter: down 5.64%

Company Overview

Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways. The company's product in the pipeline include bardoxolone methyl; Omaveloxolone and others.


Related Articles (RETA)

View Comments and Join the Discussion!

Posted-In: Earnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at